

Subject index

Volume 29 (1996)

Acute respiratory infection; Common cold; Effect size; Experimental design; Rhinovirus; Treatment; Variance **29, 287**

Acyclovir; Clinical trial design; Prednisone; Herpes zoster **29, 67**

Acyclovir; Topical antiviral efficacies; HSV-1; C* concept; Animal model **29, 279**

AIDS; Clinical trial; Combination antiviral therapy; Cytomegalovirus retinitis; Foscarnet; Ganciclovir **29, 69**

Alpha interferon; Hepatitis B virus; Combination therapies **29, 49**

Alpha-interferon; Interleukin-2; HIV; Cytokine **29, 105**

AMT; β -D-uridine; CFU-GM; AZT; FLT **29, 261**

Analytical methods; Antiviral; Chemotherapy; Drug combinations; Review; Synergy **29, 41**

Animal; Cytomegalovirus; Combination-therapy; Ganciclovir; Hyper-immune-serum **29, 61**

Animal model; Acyclovir; Topical antiviral efficacies; HSV-1; C* concept **29, 279**

Animal model; Protease inhibitor; Murine retrovirus; Murine leukemia virus **29, 175**

Animal models; Combination antiviral therapy **29, 57**

Anti-HIV agents; Bicyclams; Resistance; JM3100 **29, 297**

Antisense; Epstein-Barr virus; Latency; Reactivation; BZLF1; Phosphorothioates **29, 243**

Antiviral agent; Infectivity; Immunofluorescence assay; Plaque assay; Bellenamine **29, 163**

Antiviral agents; Lactoferrin; Herpes simplex virus type 1 (HSV-1); Viral adsorption **29, 221**

Antiviral; Analytical methods; Chemotherapy; Drug combinations; Review; Synergy **29, 41**

Antiviral chemotherapy; Drug resistance; HIV **29, 31**

Antiviral; Cidofovir; Cytomegalovirus; Bioavailability; Clinical trial **29, 153**

Antiviral; Murine cytomegalovirus; Cyclobutylguanine; Nucleoside; LP-BM5 retrovirus complex; Immunocompromised host **29, 233**

Antivirals; Secretory leukocyte protease inhibitor (SLPI); Lymphocytes; Monocytes; Human immunodeficiency virus type-1 (HIV-1); Saliva **29, 269**

Antiviral; Salmonid virus; Infectious pancreatic necrosis virus (IPNV); In vitro evaluation **29, 309**

AZT; β -D-uridine; CFU-GM; AMT; FLT **29, 261**

Bellenamine; Antiviral agent; Infectivity; Immunofluorescence assay; Plaque assay **29, 163**

Bicyclams; Anti-HIV agents; Resistance; JM3100 **29, 297**

Bicyclams; Human immunodeficiency virus; Entry **29, 209**

Bioavailability; Cidofovir; Antiviral; Cytomegalovirus; Clinical trial **29, 153**

BZLF1; Epstein-Barr virus; Latency; Reactivation; Antisense; Phosphorothioates **29**, 243

Cartesian coordinate plot; Viral burden; CD4 + cell; Individual therapy response; Virologic response modifier; Immunologic response modifier; Clinical trial design **29**, 83

C* concept; Acyclovir; Topical antiviral efficacies; HSV-1; Animal model **29**, 279

CD4 + cell; Saquinavir; Zidovudine; Zalcitabine; Phase II clinical trial; Combination therapy; Quantitative HIV-1 microculture; HIV-1 RNA **29**, 99

CD4 + cell; Viral burden; Cartesian coordinate plot; Individual therapy response; Virologic response modifier; Immunologic response modifier; Clinical trial design **29**, 83

CFU-GM; β -D-uridine; AZT; AMT; FLT **29**, 261

Chemotherapy; Analytical methods; Antiviral; Drug combinations; Review; Synergy **29**, 41

Cidofovir; Antiviral; Cytomegalovirus; Bioavailability; Clinical trial **29**, 153

Clinical efficacy, famciclovir; Famciclovir; Safety testing, famciclovir; Herpes simplex, clinical studies; Varicella-zoster, clinical studies **29**, 141

Clinical trial; AIDS; Combination antiviral therapy; Cytomegalovirus retinitis; Foscarnet; Ganciclovir **29**, 69

Clinical trial; Cidofovir; Antiviral; Cytomegalovirus; Bioavailability **29**, 153

Clinical trial design; Acyclovir; Prednisone; Herpes zoster **29**, 67

Clinical trial design; Viral burden; CD4 + cell; Cartesian coordinate plot; Individual therapy response; Virologic response modifier; Immunologic response modifier **29**, 83

Clinical trials; Screening protocol; Combination therapies **29**, 115

Clinical Trial Subcommittee; HIV; Combination therapies; Inter-Company Collaboration for AIDS Drug Development **29**, 119

CLASS; Pharmacodynamics; Pharmacokinetics; Drug-drug interactions **29**, 65

Combination antiviral therapy; AIDS; Clinical trial; Cy-

tomegalovirus retinitis; Foscarnet; Ganciclovir **29**, 69

Combination antiviral therapy; Animal models **29**, 57

Combination therapies; Clinical trials; Screening protocol **29**, 115

Combination therapies; Hepatitis B virus; Alpha interferon **29**, 49

Combination therapies; HIV; Inter-Company Collaboration for AIDS Drug Development Clinical Trial Subcommittee **29**, 119

Combination therapies; HIV-1; RT-inhibitors; HIV-1 protease inhibitors **29**, 35

Combination-therapy; Cytomegalovirus; Ganciclovir; Hyperimmune-serum; Animal **29**, 61

Combination therapy; HIV; RT inhibitors; Protease inhibitors **29**, 87

Combination therapy; Saquinavir; Zidovudine; Zalcitabine; Phase II clinical trial; CD4 + cell; Quantitative HIV-1 microculture; HIV-1 RNA **29**, 99

Common cold; Acute respiratory infection; Effect size; Experimental design; Rhinovirus; Treatment; Variance **29**, 287

Cyclobutylguanine; Murine cytomegalovirus; Antiviral; Nucleoside; LP-BM5 retrovirus complex; Immunocompromised host **29**, 233

Cytokine; Alpha-interferon; Interleukin-2; HIV **29**, 105

Cytomegalovirus; Cidofovir; Antiviral; Bioavailability; Clinical trial **29**, 153

Cytomegalovirus; Combination-therapy; Ganciclovir; Hyperimmune-serum; Animal **29**, 61

Cytomegalovirus retinitis; AIDS; Clinical trial; Combination antiviral therapy; Foscarnet; Ganciclovir **29**, 69

Cytomegalovirus; Retinitis; Ganciclovir; Foscarnet **29**, 73

β -D-uridine; CFU-GM; AZT; AMT; FLT **29**, 261

Didanosine; HIV-1; Hydroxyurea **29**, 111

Drug combinations; Analytical methods; Antiviral; Chemotherapy; Review; Synergy **29**, 41

- Drug-drug interactions**; CLASS; Pharmacodynamics; Pharmacokinetics **29**, 65
- Drug resistance**; Antiviral chemotherapy; HIV **29**, 31
- Effect size**; Acute respiratory infection; Common cold; Experimental design; Rhinovirus; Treatment; Variance **29**, 287
- Entry**; Human immunodeficiency virus; Bicyclams **29**, 209
- Epstein-Barr virus**; Latency; Reactivation; BZLF1; Antisense; Phosphorothioates **29**, 243
- Experimental design**; Acute respiratory infection; Common cold; Effect size; Rhinovirus; Treatment; Variance **29**, 287
- Famciclovir**; Clinical efficacy, famciclovir; Safety testing, famciclovir; Herpes simplex, clinical studies; Varicella-zoster, clinical studies **29**, 141
- Fialuridine**; FIAU; Mitochondrial toxicity; Hepatitis B **29**, 125
- FIAU**; Fialuridine; Mitochondrial toxicity; Hepatitis B **29**, 125
- FLT**; β -D-uridine; CFU-GM; AZT; AMT **29**, 261
- Foscarnet**; AIDS; Clinical trial; Combination antiviral therapy; Cytomegalovirus retinitis; Ganciclovir **29**, 69
- Foscarnet**; Cytomegalovirus; Retinitis; Ganciclovir **29**, 73
- Ganciclovir**; AIDS; Clinical trial; Combination antiviral therapy; Cytomegalovirus retinitis; Foscarnet **29**, 69
- Ganciclovir**; Cytomegalovirus; Combination-therapy; Hyper-immune-serum; Animal **29**, 61
- Ganciclovir**; Cytomegalovirus; Retinitis; Foscarnet **29**, 73
- Glycosylation**; Heat shock proteins; Interferon; Prostaglandins; Vesicular Stomatitis Virus **29**, 187
- Heat shock proteins**; Glycosylation; Interferon; Prostaglandins; Vesicular Stomatitis Virus **29**, 187
- Hepatitis B**; FIAU; Fialuridine; Mitochondrial toxicity **29**, 125
- Hepatitis B virus**; Alpha interferon; Combination therapies **29**, 49
- Herpes simplex, clinical studies**; Famciclovir; Clinical efficacy, famciclovir; Safety testing, famciclovir; Varicella-zoster, clinical studies **29**, 141
- Herpes simplex virus type 1 (HSV-1)**; Lactoferrin; Antiviral agents; Viral adsorption **29**, 221
- Herpes zoster**; Clinical trial design; Acyclovir; Prednisone **29**, 67
- HIV**; Alpha-interferon; Interleukin-2; Cytokine **29**, 105
- HIV**; Antiviral chemotherapy; Drug resistance **29**, 31
- HIV**; Combination therapies; Inter-Company Collaboration for AIDS Drug Development; Clinical Trial Subcommittee **29**, 119
- HIV-1**; Combination therapies; RT-inhibitors; HIV-1 protease inhibitors **29**, 35
- HIV**; Combination therapy; RT inhibitors; Protease inhibitors **29**, 87
- HIV-1**; Hydroxyurea; Didanosine **29**, 111
- HIV-1 protease inhibitors** **HIV-1**; HIV-1; Combination therapies; RT-inhibitors **29**, 35
- HIV-1 protinease**; Saquinavir; Inhibitors **29**, 95
- HIV-1**; Protease inhibitors; 141W94 (VX-478) **29**, 53
- HIV-1 RNA**; Saquinavir; Zidovudine; Zalcitabine; Phase II clinical trial; Combination therapy; CD4 + cell; Quantitative HIV-1 microculture **29**, 99
- HIV**; Saquinavir; Zidovudine **29**, 91
- HSV-1**; Acyclovir; Topical antiviral efficacies; C* concept; Animal model **29**, 279
- Human immunodeficiency virus**; Entry; Bicyclams **29**, 209
- Human immunodeficiency virus type-1 (HIV-1)**; Secretory leukocyte protease inhibitor (SLPI); Lymphocytes; Monocytes; Antivirals; Saliva **29**, 269
- Hydroxyurea**; HIV-1; Didanosine **29**, 111
- Hyper-immune-serum**; Cytomegalovirus; Combination-therapy; Ganciclovir; Animal **29**, 61
- Immunocompromised host**; Murine cytomegalovirus; Cyclobutylguanine; Antiviral; Nucleoside; LP-BM5 retrovirus complex **29**, 233

Immunologic response modifier; Viral burden; CD4 + cell; Cartesian coordinate plot; Individual therapy response; Virologic response modifier; Clinical trial design **29**, 83

Immunofluorescence assay; Antiviral agent; Infectivity; Plaque assay; Bellenamine **29**, 163

Individual therapy response; Viral burden; CD4 + cell; Cartesian coordinate plot; Virologic response modifier; Immunologic response modifier; Clinical trial design **29**, 83

Infectious pancreatic necrosis virus (IPNV); Salmonid virus; Antiviral; In vitro evaluation **29**, 309

Infectivity; Antiviral agent; Immunofluorescence assay; Plaque assay; Bellenamine **29**, 163

Inhibitors; HIV-1 protease; Saquinavir **29**, 95

Inter-Company Collaboration for AIDS Drug Development; HIV; Combination therapies; Clinical Trial Subcommittee **29**, 119

Interferon; Glycosylation; Heat shock proteins; Prostaglandins; Vesicular Stomatitis Virus **29**, 187

Interferon- γ ; Liposomes; Influenza infection; Macrophage **29**, 199

Interleukin-2; Alpha-interferon; HIV; Cytokine **29**, 105

Influenza infection; Liposomes; Interferon- γ ; Macrophage **29**, 199

In vitro evaluation; Salmonid virus; Infectious pancreatic necrosis virus (IPNV); Antiviral **29**, 309

JM3100; Anti-HIV agents; Bicyclams; Resistance **29**, 297

Lactoferrin; Herpes simplex virus type 1 (HSV-1); Antiviral agents; Viral adsorption **29**, 221

Latency; Epstein-Barr virus; Reactivation; BZLF1; Antisense; Phosphorothioates **29**, 243

Liposomes; Interferon- γ ; Influenza infection; Macrophage **29**, 199

LP-BM5 retrovirus complex; Murine cytomegalovirus; Cyclobutylguanine; Antiviral; Nucleoside; Immunocompromised host **29**, 233

Lymphocytes; Secretory leukocyte protease inhibitor (SLPI);

Monocytes; Human immunodeficiency virus type-1 (HIV-1); Antivirals; Saliva **29**, 269

Macrophage; Liposomes; Interferon- γ ; Influenza infection **29**, 199

Mitochondrial toxicity; FIAU; Fialuridine; Hepatitis B **29**, 125

Monocytes; Secretory leukocyte protease inhibitor (SLPI); Lymphocytes; Human immunodeficiency virus type-1 (HIV-1); Antivirals; Saliva **29**, 269

Murine cytomegalovirus; Cyclobutylguanine; Antiviral; Nucleoside; LP-BM5 retrovirus complex; Immunocompromised host **29**, 233

Murine leukemia virus; Protease inhibitor; Animal model; Murine retrovirus **29**, 175

Murine retrovirus; Protease inhibitor; Animal model; Murine leukemia virus **29**, 175

Nucleoside; Murine cytomegalovirus; Cyclobutylguanine; Antiviral; LP-BM5 retrovirus complex; Immunocompromised host **29**, 233

Pharmacodynamics; CLASS; Pharmacokinetics; Drug-drug interactions **29**, 65

Pharmacokinetics; CLASS; Pharmacodynamics; Drug-drug interactions **29**, 65

Phase II clinical trial; Saquinavir; Zidovudine; Zalcitabine; Combination therapy; CD4 + cell; Quantitative HIV-1 microculture; HIV-1 RNA **29**, 99

Phosphorothioates; Epstein-Barr virus; Latency; Reactivation; BZLF1; Antisense **29**, 243

Plaque assay; Antiviral agent; Infectivity; Immunofluorescence assay; Bellenamine **29**, 163

Prednisone; Clinical trial design; Acyclovir; Herpes zoster **29**, 67

Prostaglandins; Glycosylation; Heat shock proteins; Interferon; Vesicular Stomatitis Virus **29**, 187

Protease inhibitor; Animal model; Murine retrovirus; Murine leukemia virus **29**, 175

Protease inhibitors; HIV; Combination therapy; RT inhibitors **29**, 87

Protease inhibitors; HIV-1; 141W94 (VX-478) **29**, 53

Quantitative HIV-1 microculture; Saquinavir; Zidovudine; Zalcitabine; Phase II clinical trial; Combination therapy; CD4 + cell; HIV-1 RNA **29**, 99

Reactivation; Epstein-Barr virus; Latency; BZLF1; Antisense; Phosphorothioates **29**, 243

Resistance; Anti-HIV agents; Bicyclams; JM3100 **29**, 297

Retinitis; Cytomegalovirus; Ganciclovir; Foscarnet **29**, 73

Review; Analytical methods; Antiviral; Chemotherapy; Drug combinations; Synergy **29**, 41

Rhinovirus; Acute respiratory infection; Common cold; Effect size; Experimental design; Treatment; Variance **29**, 287

RT-inhibitors; HIV-1; Combination therapies; HIV-1 protease inhibitors **29**, 35

RT inhibitors; HIV; Combination therapy; Protease inhibitors **29**, 87

Safety testing, famciclovir; Famciclovir; Clinical efficacy, famciclovir; Herpes simplex, clinical studies; Varicella-zoster, clinical studies **29**, 141

Saliva; Secretory leukocyte protease inhibitor (SLPI); Lymphocytes; Monocytes; Human immunodeficiency virus type-1 (HIV-1); Antivirals **29**, 269

Salmonid virus; Infectious pancreatic necrosis virus (IPNV); Antiviral; In vitro evaluation **29**, 309

Saquinavir; HIV-1 protease; Inhibitors **29**, 95

Saquinavir; HIV; Zidovudine **29**, 91

Saquinavir; Zidovudine; Zalcitabine; Phase II clinical trial; Combination therapy; CD4 + cell; Quantitative HIV-1 microculture; HIV-1 RNA **29**, 99

Screening protocol; Clinical trials; Combination therapies **29**, 115

Secretory leukocyte protease inhibitor (SLPI); Lymphocytes; Monocytes; Human immunodeficiency virus type-1 (HIV-1); Antivirals; Saliva **29**, 269

Synergy; Analytical methods; Antiviral; Chemotherapy; Drug combinations; Review **29**, 41

Topical antiviral efficacies; Acyclovir; HSV-1; C* concept; Animal model **29**, 279

Treatment; Acute respiratory infection; Common cold; Effect size; Experimental design; Rhinovirus; Variance **29**, 287

Variance; Acute respiratory infection; Common cold; Effect size; Experimental design; Rhinovirus; Treatment **29**, 287

Varicella-zoster, clinical studies; Famciclovir; Clinical efficacy, famciclovir; Safety testing, famciclovir; Herpes simplex, clinical studies **29**, 141

Vesicular Stomatitis Virus; Glycosylation; Heat shock proteins; Interferon; Prostaglandins **29**, 187

Viral adsorption; Lactoferrin; Herpes simplex virus type 1 (HSV-1); Antiviral agents **29**, 221

Viral burden; CD4 + cell; Cartesian coordinate plot; Individual therapy response; Virologic response modifier; Immunologic response modifier; Clinical trial design **29**, 83

Virologic response modifier; Viral burden; CD4 + cell; Cartesian coordinate plot; Individual therapy response; Immunologic response modifier; Clinical trial design **29**, 83

141W94 (VX-478); HIV-1; Protease inhibitors **29**, 53

Zalcitabine; Saquinavir; Zidovudine; Phase II clinical trial; Combination therapy; CD4 + cell; Quantitative HIV-1 microculture; HIV-1 RNA **29**, 99

Zidovudine; HIV; Saquinavir **29**, 91

Zidovudine; Saquinavir; Zalcitabine; Phase II clinical trial; Combination therapy; CD4 + cell; Quantitative HIV-1 microculture; HIV-1 RNA **29**, 99

Screening protocol; Clinical trials; Combination therapies **29**, 115

Secretory leukocyte protease inhibitor (SLPI); Lymphocytes; Monocytes; Human immunodeficiency virus type-1 (HIV-1); Antivirals; Saliva **29**, 269

Synergy; Analytical methods; Antiviral; Chemotherapy; Drug combinations; Review **29**, 41

Topical antiviral efficacies; Acyclovir; HSV-1; *C* concept*; *Animal model* **29**, 279

Treatment; Acute respiratory infection; Common cold; Effect size; Experimental design; Rhinovirus; Variance **29**, 287

Variance; Acute respiratory infection; Common cold; Effect size; Experimental design; Rhinovirus; Treatment **29**, 287

Varicella-zoster, clinical studies; Famciclovir; Clinical efficacy, famciclovir; Safety testing, famciclovir; Herpes simplex, clinical studies **29**, 141

Vesicular Stomatitis Virus; Glycosylation; Heat shock proteins; Interferon; Prostaglandins **29**, 187

Viral adsorption; Lactoferrin; Herpes simplex virus type 1 (HSV-1); Antiviral agents **29**, 221

Viral burden; CD4 + cell; Cartesian coordinate plot; Individual therapy response; Virologic response modifier; Immunologic response modifier; Clinical trial design **29**, 83

Virologic response modifier; Viral burden; CD4 + cell; Cartesian coordinate plot; Individual therapy response; Immunologic response modifier; Clinical trial design **29**, 83

141W94 (VX-478); HIV-1; Protease inhibitors **29**, 53

Zalcitabine; Saquinavir; Zidovudine; Phase II clinical trial; Combination therapy; CD4 + cell; Quantitative HIV-1 microculture; HIV-1 RNA **29**, 99

Zidovudine; HIV; Saquinavir **29**, 91

Zidovudine; Saquinavir; Zalcitabine; Phase II clinical trial; Combination therapy; CD4 + cell; Quantitative HIV-1 microculture; HIV-1 RNA **29**, 99